Literature DB >> 4945919

Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease.

D E Silver, A L Sahs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4945919

Source DB:  PubMed          Journal:  Trans Am Neurol Assoc        ISSN： 0065-9479


× No keyword cloud information.
  5 in total

1.  ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.

Authors:  Rajesh Pahwa; Caroline M Tanner; Robert A Hauser; Stuart H Isaacson; Paul A Nausieda; Daniel D Truong; Pinky Agarwal; Keith L Hull; Kelly E Lyons; Reed Johnson; Mary Jean Stempien
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

Review 2.  NMDA receptors in clinical neurology: excitatory times ahead.

Authors:  Lorraine V Kalia; Suneil K Kalia; Michael W Salter
Journal:  Lancet Neurol       Date:  2008-08       Impact factor: 44.182

3.  Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).

Authors:  Rajesh Pahwa; Caroline M Tanner; Robert A Hauser; Kapil Sethi; Stuart Isaacson; Daniel Truong; Lynn Struck; April E Ruby; Natalie L McClure; Gregory T Went; Mary Jean Stempien
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

4.  Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).

Authors:  Wolfgang Oertel; Karla Eggert; Rajesh Pahwa; Caroline M Tanner; Robert A Hauser; Claudia Trenkwalder; Reinhard Ehret; Jean Philippe Azulay; Stuart Isaacson; Larissa Felt; Mary Jean Stempien
Journal:  Mov Disord       Date:  2017-08-21       Impact factor: 10.338

Review 5.  Amantadine in Parkinson's disease.

Authors:  N Crosby; K H Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.